Rare disease start-up Harmony raises $270mm in early equity funding
Concurrent with procuring an exclusive US license to Bioprojet's narcolepsy candidate pitolisant, Harmony Biosciences LLC (developing rare disease therapeutics) announced it raised $270mm in equity financing (assumed to be its Series A round) from 29 investors, including Valor Equity Partners, Fidelity Management & Research, HBM Healthcare Investments, Vivo Capital, venBio Partners, Novo Holdings, and Nan Fung Life Sciences.
- Drug Discovery Tools
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.